On May 15th, the reporter learned from National Equities Exchange Corporation that as of May 14th, 15 companies listed on the New Third Board have disclosed their intended authorized issuance announcements. Among them, two listed companies have disclosed targeted issuance prospectuses and have chosen to apply simplified review procedures to accelerate the pace of financing. One of the listed companies has been approved, and it only took 4 days from the disclosure of the targeted issuance prospectus by the company to the letter of approval for the targeted issuance. In the comprehensive registration system reform in 2023, in response to the practical characteristics of small and medium-sized enterprises with small single financing scale, frequent and urgent demand, the National Equities Exchange Corporation has introduced a relevant system for authorizing issuance to apply the simplified review procedure. On the one hand, based on the authorization of the annual shareholders' meeting to the board of directors to choose an opportunity for issuance, the board of directors does not need to hold a separate extraordinary shareholders' meeting after considering and passing the issuance proposal. Directly submitting application materials can save internal decision-making time of the enterprise; On the other hand, when the board of directors deliberates, if the issuance target has been determined, there is no negative list situation, and the application materials can be submitted within 20 days, the National Equities Exchange Company will accept it on the second day and issue a letter on the third day, further reducing the review time and effectively improving the financing efficiency of the enterprise. The two listed companies that have chosen to apply the simplified review procedure for authorized issuance are Anbang Pharmaceutical and Heijinger. The former issued 706000 shares of stock to three external investors at a price of 14.17 yuan per share, raising 10.004 million yuan; The latter plans to issue 654700 shares of stock to CITIC Construction Investment Co., Ltd. at a price of 22.91 yuan per share, raising approximately 15 million yuan, all of which will be used to supplement working capital. The above issuance application of Anbang Pharmaceutical has been approved. The main business of the company is the R&D, production and sales of traditional Chinese patent medicines and simple preparations, chemical medicine and API, and it is a specialized, special and new "little giant" enterprise in Hunan Province. The company currently has 45 drug approval numbers, of which 4 products are exclusive varieties, 2 products are exclusive dosage forms, 7 products are listed in the national basic drug catalog, 16 products are listed in the national basic medical insurance, work injury insurance, and maternity insurance drug catalog, and has 19 OTC products and 4 dual cross drug products. In 2022, the company achieved a revenue of 318 million yuan, a year-on-year increase of 27.37%; The net profit attributable to the parent company was 33.4679 million yuan, a year-on-year increase of 127.74%. Higginger is a contract research organization, namely clinical CRO enterprise, which specializes in providing phase IIV clinical research and related technical services for pharmaceutical enterprises, medical device enterprises and new drug research institutions. In March 2022, the company was recognized as a "specialized, refined, and innovative" small and medium-sized enterprise in Beijing. In 2022, the company achieved a revenue of 434 million yuan, a year-on-year increase of 29.52%; The net profit attributable to the parent company was 42.4247 million yuan, a year-on-year increase of 245.87%. Specialized, refined, and innovative enterprise financing highlights the overall profitability of the 15 listed companies, with an average operating revenue of 289 million yuan and an average net profit of 20.7 million yuan in 2022. In addition to Anbang Pharmaceuticals and Higginger, there are also 4 specialized, refined, and innovative enterprises among these 15 listed companies. In fact, investors have invested more attention and support in specialized, refined, and new enterprises on the New Third Board